WHAT IS CLAIMED IS:

1. A method of treating a B cell hyperproliferative disorder, the method comprising:

administering to a patient an effective dose of an antibody that specifically binds to an antigen present on said B cells; and IFN-γ (gamma interferon).

2. The method according to Claim 1, wherein said B cell hyperproliferative disease is a Non-Hodgkin's lymphoma.

3. The method according to Claim 1, wherein said antibody is a monoclonal antibody.

4. The method according to Claim 1, wherein said antibody is a humanized monoclonal antibody.

5. The method according to Claim 1, wherein said antigen present on said B cells is CD20.

6. The method according to Claim 1, wherein said antibody is administered at a dose of 0.001 to 30 mg/kg.

7. The method according to Claim 1, wherein said IFN-γ is human IFN-γ.

8. The method according to Claim 7, wherein said IFN-γ is administered at a dose of from 0.5 $\mu g/m^2$ to about 500 $\mu g/m^2$.

9. The method according to Claim 7, wherein administration of said IFN-γ is initiated at least one week prior to initiation of treatment with said antibody.

10. A composition comprising:

an antibody that binds to an antigen present on B cells; and

gamma interferon.

11. The composition of claim 10, wherein said antibody is a monoclonal antibody.

12. The composition of claim 10, wherein said antibody is an anti-CD20 antibody.

13. The composition of claim 10, wherein said antibody is in an amount sufficient to deliver a unit dose of about 0.001 to about 30 mg/kg.

14. The composition of claim 10, wherein said gamma interferon is human gamma interfereon.

15. The composition of claim 10, wherein said gamma interfereon is in an amount sufficient to deliver a unit dose of about 0.5 micrograms/m^2 to about 500 micrograms /m^2.

16. Use of the composition of any of claims 10-15 as a medicament for the treatment of a B cell proliferative disorder.

17. Use according to claim 16, wherein the disorder is a Non-Hodgkin's lymphoma.